News / Events :: BioXcel Therapeutics, Inc. (BTAI)

Recent News View All News

BioXcel Therapeutics Announces BXCL501 Met Primary Endpoint in Phase 1b Placebo-Controlled Trial in the Treatment of Agitation in Patients with Schizophrenia

July 22, 2019

BioXcel Therapeutics Added to Russell 3000® Index

July 1, 2019

Upcoming Events View IR Calendar

Canaccord Genuity's 39th Annual Growth Conference

Aug 7 – Aug 8, 2019

View IR Calendar

Email Alerts

Sign up for email alerts for Press Releases & SEC Filings